SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SCYNEXIS Inc.

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.